Sphingosine-
1
-phosphate analogs that are potent, and selective agonists at one or more S1P receptors, specifically the S1P
1
receptor type are provided. The disclosed compounds include an optional phosphate moiety as well as compounds with hydrolysis-resistant phosphate surrogates such as phosphonates, alpha-substituted phosphonates, and phosphothionates.